Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Epidemiology of Huntington’s Disease (HD) in the US Medicare Population
Movement Disorders
P5 - Poster Session 5 (8:00 AM-9:00 AM)
3-006

To estimate the current incidence and prevalence of HD among Medicare beneficiaries in the US. 
HD is a genetic, progressive, neurodegenerative disease with onset usually occurring between 30 and 50 years of age; however, late-onset HD can occur among older patients. Few estimates of HD epidemiology in the US exist: one study estimated 1989-1990 incidence and prevalence in a single US state as 0.3 and 1.9 per 100,000 person-years or persons; a recent study of commercially insured patients calculated incidence and prevalence at 1.2 and 6.5 per 100,000, respectively. Given this dearth of evidence, particularly for older patients, research is needed to generate current estimates in US populations.

Medicare Research Identifiable Files (100%) were used to identify beneficiaries >65 years who were diagnosed with HD based on the presence of >1 medical claim with a diagnosis for HD (ICD-10-CM: G10) in 2017. Prevalence was calculated as the number of HD cases in 2017 divided by all beneficiaries enrolled in Fee-for-Service Medicare and Part D in 2017 (reported per 100,000 persons). Incidence was calculated as the number of new HD cases in 2017 (i.e., no HD claim in 2016) divided by total at-risk patient-years from January 1st to diagnosis (cases) or enrollment end (non-cases) in 2017 (reported per 100,000 person-years). Estimates were stratified by sex.
HD incidence among beneficiaries in 2017 was 6.1 per 100,000 person-years (females: 5.9 vs. males: 6.4). HD prevalence in 2017 was 13.1 per 100,000 persons (females: 12.6 vs. males: 13.7).
This study of HD epidemiology among Medicare beneficiaries is the first of its kind. These estimates of incidence and prevalence are higher than previously reported in the US; this may be due to diagnostic changes over time or differences in studied populations. Future estimates will be stratified by age and disease stage.
Authors/Disclosures
Alex Exuzides
PRESENTER 		Alex Exuzides has nothing to disclose.
No disclosure on file
No disclosure on file
Eunice Chang No disclosure on file
No disclosure on file